Cambridge Cognition Holdings PLC (LSE:COG) Share Price

Company Profile

Business description
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
Contact
Tunbridge Lane, Tunbridge Court
Bottisham
CambridgeCB25 9TU
GBR
T: +44 1223810700
E: [email protected]
https://www.cambridgecognition.com
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
74

Recommended

We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.

Brian Colello, CPA | 24 August 2026

Profits flatten as airport ramps up redevelopment.

Angus Hewitt, CFA | 24 August 2026

Income appeal backed by growth projects.

Adrian Atkins | 24 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,316.70	9.20	0.10%
CAC 40	8,453.01	31.42	-0.37%
DAX 40	26,106.60	29.96	-0.11%
Dow JONES (US)	53,353.52	76.51	0.14%
FTSE 100	10,854.32	37.76	0.35%
HKSE	25,517.33	492.13	-1.89%
NASDAQ	26,050.57	129.88	-0.50%
Nikkei 225	65,528.09	488.27	-0.74%
NZX 50 Index	13,881.88	90.78	-0.65%
S&P 500	7,657.78	16.59	-0.22%
S&P/ASX 200	9,103.10	9.90	0.11%
SSE Composite Index	3,882.01	23.19	-0.59%